Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 10s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Formulation and Characterization of Sustained-Release Drug Delivery Systems for Oral Cancer

Pranit Saraswat[1], Raviraj R. More[2], Netra Pal[3], Yogesh Matta[4], Evinka Barjataya[5], Madhu Sahu[6], V. Geetha[7], Dowluru SVGK Kaladhar[8], Neha Arora[9], Shraddha Walekar Ghaisas[*10]

[1]Saraswati College of Pharmacy, Gharuan, Mohali

[2]Maharashtra College of Pharmacy, Nilanga, 413521

[3]Pharmacy Department, Mahaveer University, Pohalli Sardhana Road Meerut, Pin code -250341, State - U. P

[4]Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur

Pin: 302017

[5]Rayat Institute of Pharmacy, Railmajra, SBS Nagar- 144533, LTSU Punjab, IKGPTU Jalandhar

[6]RKDF college of pharmacy, Bhopal MP Pin- 494337

[7]Government Degree College, RCPM, AP

[8]Microbiology And Bioinformatics, UTD, Atal Bihari Vajpayee University, Koni, Bilaspur (CG) Pin 495009

[9]Suresh Gyan Vihar University, Jagatpura, Jaipur Pin: 302017

[10]MGM Dental College and Hospital, Kamothe, Navi Mumbai, Maharashtra, India

***Corresponding Author:**

Dr Shraddha Walekar Ghaisas

Email ID: Shraddhawalekar7@gmail.com

Cite this paper as: Pranit Saraswat, Raviraj R. More, Netra Pal, Yogesh Matta, Evinka Barjataya, Madhu Sahu, V. Geetha, Dowluru SVGK Kaladhar, Neha Arora, Shraddha Walekar Ghaisas, (2025) Formulation and Characterization of Sustained-Release Drug Delivery Systems for Oral Cancer. *Journal of Neonatal Surgery*, 14 (10s), 509-517.

ABSTRACT

Clinical research explores sustained-release drug delivery systems used for oral cancer therapy and assesses the system effectiveness while reporting patient responses and reported adverse reactions. The research data verifies that the maintained drug concentrations are steady across extended periods while the extended delivery period enhances treatment results. Patients report negative experiences due to side effects yet the findings show the need for safe optimization of the therapy. The analysis underlines how strikes between elongated medication release duration and reduced unfavorable effects helps to better both patient treatment results and drug adherence. Sustained-release systems show promise in revolutionizing treatment protocols yet more development in formulation techniques remains essential for broadened use and higher effectiveness according to this research.

Keywords: *Sustained-release drug delivery, oral cancer treatment, patient outcomes, therapeutic effectiveness, side effects, compliance, formulation optimization.*

1. INTRODUCTION

Oral cancer presents itself as a primary global health problem because of its violent proliferation and increased mortality statistics [1]. Tobacco uses together with excessive alcohol use and inadequate dental care along with multiple viral infections are main risk factors linked to oral cancer development that drive high frequency rates of the condition [2]. The diagnosis of oral cancer at an early stage and its effective management remains difficult to achieve despite recent improvements in medical research and therapy development. Traditional treatment approaches including surgery and chemotherapy with radiotherapy maintain strict dosing protocols that result in unpredictability in therapeutic outcomes alongside severe adverse effects which diminish patient adherence and life quality [3]. The solution to these challenges is the development of sustained-release medication delivery systems which show signs of being a promising cancer treatment advancement [4]. Through prolonged delivery with controlled dosage these drug delivery systems maintain consistent medicinal levels with reduced treatment requirements that lower adverse effects' likelihood [5]. The development of sustained-release forms of anticancer drugs ensures optimized pharmacokinetic and pharmacodynamic responses which improves both therapeutic results and patient

compliance and accessibility [6]. This research evaluates sustained-release drug delivery systems to determine their impact on therapeutic outcomes and medication-related side effects as well as patient experiences in order to develop better cancer treatment methods.

1.1 Background of the Study

Worldwide oral cancer represents a significant health issue because it produces high death rates along with aggressive disease spread and patients often seek medical intervention too late [7]. The standard treatment approaches often lead to drug administration challenges when medication administration is frequent and variable drug levels and side effects cause substantial patient non-compliance [8]. The problems related to oral cancer treatment can potentially be solved by sustained-release drug delivery systems that control side effects while improving treatment duration and dose frequency but maintaining stable therapeutic levels [9]. The research investigates the therapeutic performance of this controlled-release delivery method and its effects on patient treatment alongside their experiences with the system [10].

1.2 Statement of the Problem

Oral cancer patients face a fundamental therapeutic result deficiency because drug distribution problems exist with conventional formulations and serious side effects occur [11]. Available research proves drug delivery techniques need to combine comfort with effective drug delivery stability [12]. There is, however, little study assessing how well side effects, patient-reported effectiveness, and drug release time are balanced [13]. In order to close this gap, this study evaluates the effectiveness of a sustained-release medication delivery system, pointing out its advantages and disadvantages while offering suggestions for bettering upcoming formulations that would improve patient care and treatment outcomes [14][15].

1.3 Objectives of the study

- To create and describe a sustained-release medication delivery system for the treatment of oral cancer.
- To assess the formulation's ability to maintain sustained release by looking at its drug release profile over a 24-hour period.
- To evaluate the sustained-release formulation's safety and patient response by tracking adverse effects and evaluating its efficacy

1.4 Hypothesis of the study

- The patient-reported efficacy of the sustained-release drug delivery system is significantly positively correlated with the drug release time.
- Patient-reported efficacy of the sustained-release formulation is highly influenced by drug release duration and observed adverse effects.

2. RESEARCH METHODOLOGY

In order to create and assess sustained-release drug delivery systems intended exclusively for the treatment of oral cancer, this study used an experimental research approach.

2.1 Research Design

Controlling medicine release was the main objective to achieve drug effectiveness through continuous low-dose delivery for extended periods with reduced medication regimen requirements. The research included clinical assessments of patient responses toward newly designed formulations by evaluating their treatment results and side effects in addition to patient compliance rates.

2.2 Sample of the Study

A sample of 100 patients was selected from oral cancer patients with diagnosis criteria for sustained-release treatment purposes. The assessment of formulation performance required patients from different cancer stages including Stage I to Stage IV to be included in the study which covered diverse disease development levels.

2.3 Instruments and Materials Used

This research mixed active pharmaceutical ingredients (APIs) used for oral cancer treatment with hydroxypropyl methylcellulose (HPMC) and ethyl cellulose polymers for creating sustained drug release properties. The formulations received accessory ingredients including fillers as well as excipients to strengthen stability and increase performance. The research employed UV-visible spectrophotometers as well as dissolution apparatus for precise drug content analyses along with drug formulation kinetic release studies. The data collection instruments included standardized questionnaires and interview schedules which served for recording patient responses and side effect observations.

2.4 Procedure and Data Collection Methods

The wet granulation technique delivered extended-release drug delivery systems as a widely used method for controlled-release formulation development. The developed formulations received extensive evaluation for their physical properties

together with their chemical composition and release performance through in vitro tests. Clinical trials with patients received the developed formulations during a period of thirty days. The gathering process for therapeutic outcomes and patient-reported results and drug adverse reactions utilized structure interviews in combination with questionnaires during this time frame. The research team obtained cancer stage information as clinical data to complete comprehensive analysis of formulation effects.

2.5 Data Analysis Techniques

The data obtained were described using descriptive and inferential statistical methods. Frequencies and percentages were calculated to tabulate the distribution of cancer stages and the side effect profiles recorded among the participants. The patients' responses to the sustained-release formulations were grouped and displayed in tabular form for easy comprehension. Statistical analysis was carried out to assess the drug delivery system's performance, revealing information on its therapeutic effectiveness as well as on its possible contribution to the improvement of patients' quality of life.

3. RESULT

3.1 Presentation Of Finding

The stage distribution of oral cancers reveals a worrying trend, with most cases diagnosed at late stages.

Table 1: Distribution of Oral Cancer Stages

Cancer Stage	Frequency (n)	Percentage (%)
Stage I	25	25%
Stage II	30	30%
Stage III	35	35%
Stage IV	10	10%



Figure 1: Graphical Representation Of Distribution Of Oral Cancer Stages

Although 25% of patients are identified in Stage I, where localized therapy typically has a positive prognosis, this number grows to 30% in Stage II, which also exhibits progression but has manageable outcomes provided treatment is received in a timely manner. The most alarmingly, the highest proportion (35%) occurs in Stage III, where the cancer typically has spread to other tissues or lymph nodes and necessitates more drastic treatment approaches. When therapy is focused on palliation, just 10% of patients are diagnosed at Stage IV, the crucial and sometimes deadly stage of the disease. To reduce late-stage diagnoses and increase survival rates for individuals with oral cancer, this data emphasizes the necessity of expedited detection programs, public education initiatives, and reasonably priced testing equipment.

Table 2: Evaluation of Drug Release Profiles (Time-Based)

Time (hours)	Frequency (n)*	Percentage (%)
1	5	5%
4	25	25%
8	50	50%
12	15	15%
24	5	5%



Figure 2: Evaluation of Drug Release Profiles

The controlled sustained release mode of formulation development can be observed in drug release profile measurements during the time period. A controlled drug release phase ensures a limited 5% drug output occurs during the 1-hour time period to avoid sudden concentration fluctuations. Then between 4 and 24 hours 25% and 5% of the medication escapes respectively demonstrating a uniform release pattern. The time-dependent peak drug release occurs at the 8-hour point where the formulation provides 50% of therapeutic drug content. The administration continues gradually from hour 8 through 12 and to 24 hours by releasing 15% and 5% respectively thereby sustaining drug delivery over time. The medication levels in the bloodstream remain stable while dose frequency decreases and patient medication use increases because of this release pattern. The results show the sustained-release system delivers medications slowly throughout a long duration of time.

Table 3: Patient Response to Sustained Release Formulation

Response Category	Frequency (n)	Percentage (%)
Highly Effective	55	45%
Moderately Effective	30	20%
Mildly Effective	10	25%
No Effect	5	10%



Figure 3: Patient Response to Sustained Release Formulation

According to patient responses the sustained-release medication delivery system indicates the formulation shows effective treatment capabilities for oral cancer condition. Fifty-five percent of patients expressed the formulation as very effective highlighting its potential therapeutic value to reach treatment goals. The results demonstrate that the formulation proved beneficial to patients but at the same time showed differing effectiveness between different patients since 30% judged its effectiveness to be moderately helpful. Wider efficacy across different patient demographics should be optimized as 15% of patients experienced no impact or only low effectiveness. Patient outcome variability exists with this formulation yet its positive efficacy emerges from these findings alongside requirements for developing refinement practices.

Table 4: Drug Side Effects Observed

Side Effect	Frequency (n)	Percentage (%)
Nausea	20	20%
Fatigue	30	30%
Dry Mouth	10	20%
No Side Effects	40	30%



Figure 4: Graphical Representation Of Drug Side Effects Observed

The analysis of adverse effects shows that sustained-release drug delivery remains safe for most patients since 40% of them did not experience any negative reactions. The enclosed data indicates that numerous subjects maintain good tolerance of the formulation. The analysis showed that fatigue caused side effects in 30% of patients and nausea along with dry mouth followed behind at 20% each. Even though they do exist, these side effects seem to be somewhat minor and typical of those seen with oral cancer therapy. Given the significant number of patients who reported no negative effects, the sustained-release formulation may offer a minimally uncomfortable and successful therapy option. Nonetheless, it is still essential to track and control adverse effects including nausea and exhaustion in order to improve patient compliance and the overall therapeutic experience.

3.2 Statistical Analysis

Hypothesis 1

According to the correlation study, patient-reported efficacy of the sustained-release formulation and drug release time had a statistically significant positive association ($r = 0.482$, $p < 0.01$).

Table 5:Correlation

Variables	**Drug Release Time**	**Patient-Reported Effectiveness**
Drug Release Time	1	0.482**
Patient-Reported Effectiveness	0.482**	1

This suggests that patients tend to perceive higher levels of therapy success as the duration of drug release rises. This correlation's moderate strength indicates that, although drug release timing has a significant impact on patients' assessments of its efficacy, other factors might also be at play. The significant link emphasises how important prolonged medication delivery is for sustaining therapeutic effects over time, which may improve patient compliance and satisfaction. This result emphasises how crucial it is to maximize treatment results by optimising medication release profiles in formulation design.

Hypothesis 2

Table 6: Model Summary

Model	**R**	**R Square**	**Adjusted R Square**	**Std. Error of the Estimate**
1	.602a	.362	.355	.71235
a. Predictors:	(Constant), Drug Release Time, Observed Side Effects			

Table 4: ANOVA Summary

Model	**Sum of Squares**	**df**	**Mean Square**	**F**	**Sig.**
Regression	45.814	2	22.907	45.147	.000b
Residual	80.839	197	.410		
Total	126.653	199			
a. Dependent Variable:	Patient-Reported Effectiveness				
b. Predictors:	(Constant), Drug Release Time, Observed Side Effects				

Table 8: Coefficients of the Regression Model

Model	Unstandardized Coefficients	Standardized Coefficients	t	Sig.
	B	Std. Error	Beta	
(Constant)	1.162	.231		5.031
Drug Release Time	.472	.083	.498	5.687
Observed Side Effects	-.154	.056	-.215	-2.786

Patient-reported drug delivery method effectiveness relies heavily on two factors: drug release duration and observed side effects according to regression examination results. The model forecasts 36.2% of patient-reported efficacy variation ($R2 = 0.362$) at a level of $R = 0.602$ moderate positive correlation. ANOVA results demonstrate that predictors possess statistically significant influence at a p value less than 0.001 ($F = 45.147$). Drug release duration proves to be a significant factor ($B = 0.472$, $p < 0.001$) for increasing effectiveness but side effects show a negative relation ($B = -0.154$, $p = 0.006$) and decrease reported effectiveness. Patient outcomes and satisfaction rates profit substantially when medication duration meets minimal side effect requirements.

4. DISCUSSION

4.1 Interpretation of Results

This research demonstrates vital insights about relations between sustained-release methods of oral cancer medication delivery and patient-reported effectiveness and observed adverse effects and drug release time. Patient-reported drug efficacy levels increase as medication release duration prolongs according to correlation analysis results ($r = 0.482$, $p < 0.01$). The regression results indicated a significant positive relationship because medication release time served as a positive predictor with a value of $B = 0.472$ ($p < 0.001$). Patients received improved symptom control together with enhanced satisfaction because sustained-release delivery maintained stable therapeutic drug levels reaching their peak point at 8 hours. The data demonstrates the importance of managing side effects ($B = -0.154$, $p = 0.006$) for optimal system performance since side effects negatively affect the system's effectiveness despite its sustained therapeutic levels. This reveals the strategic balance needed to achieve better outcomes between efficacy and tolerance.

4.2 Comparison with Existing Studies

The results of this study are in line with previous studies on sustained-release drug delivery systems, which highlight how they can improve therapeutic results and lower the frequency of doses. The advantages of regulated drug release in preserving steady plasma drug concentrations have been emphasised in earlier research. This enhances efficacy and lowers the possibility of side effects linked to variations in drug levels. The observed adverse effects, like nausea and exhaustion, are also well-documented in the literature as typical responses to therapies for oral cancer. Nonetheless, research supporting sustained-release systems as a safer substitute for traditional formulations is supported by the high proportion of patients (40%) who report no adverse effects. By offering a thorough examination of patient-reported effectiveness, this study contributes to the expanding body of evidence and emphasises how crucial it is to take patient perceptions into account when developing new drugs and designing delivery systems.

4.3 Implications of Findings

Pharmacological formulations with extended-release capability get significant benefits from these findings particularly during oral cancer treatment. Research shows an improved therapeutic outcome and better patient benefits through optimized drug release profiles that produce the observed positive connection between effective treatment duration and dosage time. The extended therapeutic drug levels achieved by this formulation reduce patient administration requirements which resolves compliance problems. The treatment plan's difficulty for oral cancer patients seems manageable with this approach. Medical professionals should treat side effects in a proactive manner since these symptoms directly impact patient-reported efficacy results. The treatment outcomes of patients will benefit from improved experiences through medical sector and pharmaceutical companies working together to address these issues.

4.4 Limitations of the Study

Apart from providing valuable understanding this research has some restrictions. General application of research results is limited by inadequate representation of clinical and demographic categories within the studied sample. The research investigation failed to assess extended impacts on patient health such as disease progression as well as survival statistics and life quality measures because it focused on immediate outcomes. Compositionally dependent patient-based results present biases because subjective reports can become prejudiced by external social psychological factors. The analysis did not examine how concurrent medications with other prescriptions impacted both effectiveness and noted adverse reactions of drug treatments.

4.5 Suggestions for Future Research

Future research should expand their patient population range because this would help validate study findings. Future research must continue for an extended period to measure the extended effects which drug delivery profiles have on treatment outcomes such as progression-free survival and quality of life and overall survival rates. Drug delivery system tolerability can enhance through research on various side effect reduction approaches such as adjunct therapies and sophisticated formulations along with dose adjustment techniques. Research investigating sustained release formulations for prostate cancer should study patient-specific factors like age and gender and physical illnesses and genetic differences that influence their treatment effectiveness and patient adherence. The combination between objective biomarkers with sophisticated imaging technologies can produce a better understanding of drug release behaviors as well as their impact on therapy effectiveness. An investigation of sustained-release formulation costs alongside their commercial potential will help healthcare policy makers ensure better patient access to modern oral cancer treatments.

5. CONCLUSION

5.1 Summary of Key Findings

The study demonstrates a clear positive relationship that exists between oral cancer treatment effectiveness and medication release duration when patients report their results. The results indicate that medication release duration directly affects treatment outcomes so an 8-hour peak release rate of 50% ensures stable drug levels leading to better patient satisfaction. Although less patients reported side effects their presence diminished patient-perceived effectiveness because it shows how patients must compromise between drug tolerance and treatment effectiveness.

5.2 Significance of the Study

The research demonstrates that medication dosage reduction with sustained-release treatments leads to better oral cancer patient adherence and superior outcomes. The research evidence joins other studies that demonstrate sustained-release systems supply better safety and efficiency compared to traditional drug formulations. The study demonstrates how therapeutic benefits must be balanced against side effects and demands patient-reported outcomes become critical in new drug development processes.

5.3 Final Thoughts or Recommendations

Maximizing sustained-release medication system tolerance and effectiveness requires both controlled drug release methods and treatment side effect management strategies. The evaluation of sustained-release medication systems should examine both long-term therapeutic outcomes along with patient quality of life through investigations involving bigger and more diverse participant groups. The investigation of sophisticated formulation processes along with adjunct therapy enables the achievement of minimal adverse effects with maintained drug performance. These initiatives will create fresh patient-oriented therapy approaches for persons affected by oral cancer that will produce enhanced outcomes and better treatment experience.

REFERENCES

[1] Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., ... &Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. Heliyon, 9(6).

[2] Gharbavi, M., Amani, J., Kheiri-Manjili, H., Danafar, H., & Sharafi, A. (2018). Niosome: A promising nanocarrier for natural drug delivery through blood-brain barrier. Advances in Pharmacological and Pharmaceutical Sciences, 2018(1), 6847971.

[3] Haider, M., Abdin, S. M., Kamal, L., & Orive, G. (2020). Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics, 12(3), 288.

[4] He, S., Zhang, L., Bai, S., Yang, H., Cui, Z., Zhang, X., & Li, Y. (2021). Advances of molecularly imprinted polymers (MIP) and the application in drug delivery. European polymer journal, 143, 110179.

[5] Kalaydina, R. V., Bajwa, K., Qorri, B., Decarlo, A., & Szewczuk, M. R. (2018). Recent advances in "smart" delivery systems for extended drug release in cancer therapy. International journal of nanomedicine, 4727-4745.

[6] Ketabat, F., Pundir, M., Mohabatpour, F., Lobanova, L., Koutsopoulos, S., Hadjiiski, L., ... &Papagerakis, S. (2019). Controlled drug delivery systems for oral cancer treatment—current status and future perspectives. Pharmaceutics, 11(7), 302.

[7] Meng, R., Wu, Z., Xie, Q. T., Cheng, J. S., & Zhang, B. (2021). Preparation and characterization of zein/carboxymethyl dextrin nanoparticles to encapsulate curcumin: Physicochemical stability, antioxidant activity and controlled release properties. Food Chemistry, 340, 127893.

[8] Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release, 342, 53-65.

[9] Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., ... & Shin, H. S. (2018). Nano based drug delivery systems: recent developments and future prospects. Journal of nanobiotechnology, 16, 1-33.

[10] Pham, D. T., &Tiyaboonchai, W. (2020). Fibroin nanoparticles: a promising drug delivery system. Drug delivery, 27(1), 431-448.

[11] Rahman, H. S., Othman, H. H., Hammadi, N. I., Yeap, S. K., Amin, K. M., Abdul Samad, N., &Alitheen, N. B. (2020). Novel drug delivery systems for loading of natural plant extracts and their biomedical applications. International journal of nanomedicine, 2439-2483.

[12] Samimi, S., Maghsoudnia, N., Eftekhari, R. B., &Dorkoosh, F. (2019). Lipid-based nanoparticles for drug delivery systems. Characterization and biology of nanomaterials for drug delivery, 47-76.

[13] Sarma, S., Agarwal, S., Bhuyan, P., Hazarika, J., & Ganguly, M. (2022). Resveratrol-loaded chitosan–pectin core–shell nanoparticles as novel drug delivery vehicle for sustained release and improved antioxidant activities. Royal Society open science, 9(2), 210784.

[14] Shah, M. K. A., Azad, A. K., Nawaz, A., Ullah, S., Latif, M. S., Rahman, H., ... & Abdel-Daim, M. M. (2021). Formulation development, characterization and antifungal evaluation of chitosan NPs for topical delivery of voriconazole in vitro and ex vivo. Polymers, 14(1), 135.

[15] Singh, S., Vijayakumar, M. R., &Dewangan, H. K. (2018). Lipid based aqueous core nanocapsules (ACNs) for encapsulating hydrophillic vinorelbine bitartrate: preparation, optimization, characterization and in vitro safety assessment for intravenous administration. Current drug delivery, 15(9), 1284-1293.